By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday November 5. Be Prudent About Twitter ( TWTR ). Other stocks mentioned: Red Robin ( RRGB ), Starbucks ( SBUX ), SBA Communications ( SBAC ), Facebook ( FB ), Alcatel-Lucent ( ALU ),
MKM is out with an upgrade for Acorda Therapeutics ( ACOR +0.3% ) following the company ..... 2013. As for the full year, ACOR narrowed Ampyra guidance to ..... MKM's Jon LeCroy says. ACOR upgraded to Neutral from Sell
Acorda Therapeutics ( ACOR ) Q3 2013 Earnings Call October ..... Presentation Operator Welcome to the Acorda Therapeutics Third Quarter 2013 Financial Results ..... of Corporate Communications with Acorda Therapeutics . Please go ahead. Jeff Macdonald
Complete Story »
between analysts' expectations and reported results. The figures are provided by Thomson Reuters I/B/E/S. Company Name Ticker Qtr Industry Curr EPS Est EPS Act Diff EPS Rev Est Rev Act Diff Rev ACORDA THERAPEUTICS INC Q3 BIOTEC
AAP , ABC , ABX , ACOR , ALKS , ALU , ANR , ARRY , AVP , AYR , AZN , BEAM , BGCP , BLC , BUD , BYD , CAH , CI , CLX , COP , COR , COT , CRR , DGI , DISCA
Ampyra, we believe that shares of Acorda Therapeutics ( ACOR ) are worth a look. The company ..... well as a diversified pipeline, Acorda should be on investors' radar ..... long been bullish on, growth in Acorda 's main business is being stymied
By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday April 15. A Fight That Is Just Beginning: Dish Network ( DISH ), Sprint Nextel ( S ), Softbank ( SFTBF.PK ) Dish Network ( DISH ) announced a takeover bid for Sprint ( S ), and ...
this week. Fampyra, which is marketed in the United States under the trade name Ampyra by the firm's partner Acorda Therapeutics ACOR , is the first approved treatment to improve walking in patients with multiple sclerosis. Fampyra now marks
BOSTON (Reuters) - Shares of Acorda Therapeutics Inc jumped 27 percent on Thursday before being halted amid optimism the company will be granted a patent extension on its multiple sclerosis drug...